The future of Market Access strategy.
Senior Pricing & Market Access judgement, powered by AI agents
Market access no longer waits. Joint clinical assessment, tighter launch windows and reference pricing across borders mean questions arrive earlier, carry more weight, and demand answers sooner. Cellbyte was created for exactly this environment.
We approach it from both sides of the problem: the commercial judgement that market access decisions demand, and the technology that makes those decisions possible at the pace now required. Our engagements bring the two together under senior leadership, with one measure of success: the decisions our clients are able to make.
Discover our AI-powered services
Disease Landscaping / Opportunity Assessment
PICO & Comparator Assessment
Analog Research
Launch Sequence Analysis
Outcomes Validation
EU HTA / JCA Readiness
A complete indication picture: treatment pathways, unmet need, competitors, and access environment across your target markets.
Anticipate the populations, comparators, and endpoints HTA bodies will demand, based on how they ruled in comparable assessments.
Every relevant analog assessed for pricing, evidence and access outcomes, giving your strategy a documented precedent base.
The country launch order that protects your price, modeled on reference pricing rules and real interdependencies between markets.
Your value story pressure-tested against actual appraisal outcomes and payer evidence expectations before you walk into negotiations.
Anticipate the PICOs member states will submit: populations, comparators and outcomes mapped from HTA precedents, before the scoping clock starts.
Run these yourself on the platform
Cellbyte consolidates complex HTA data in a structured way, enabling users to find insights in just a few clicks. Its AI analyzes multiple analogs simultaneously, examining study designs, outcomes, and rationales, which can now be completed in few minutes instead of hours. The platform also ensures reliability by linking each insight directly to its original source.
Bayer
Gustavo Agreda Duffaut
Global Market Access Manager, Oncology Pipeline, Bayer AG